On October 20, 2025, TransThera Sciences (Nanjing), Inc. (Stock Code: 2617) disclosed that its board of directors has approved the submission of an application to the China Securities Regulatory Commission (CSRC) for a proposed H share full circulation plan.

The application involves the conversion of 44,971,128 domestic shares, representing approximately 11.33% of the company’s total issued shares as of the announcement date, held by 10 shareholders. Subject to necessary approvals and compliance with relevant regulations, these domestic shares would become H shares and be eligible for listing and trading on the Main Board of The Stock Exchange of Hong Kong Limited.

According to the announcement, the details of the conversion plan have not been finalized and are contingent upon the required procedures of the CSRC, the Stock Exchange, and other authorities. No additional shareholders’ meeting is required for approval. The company will release further updates as the process progresses.